Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits. Large vector doses also trigger an immune response as a significant fraction of the vectors fails to traffic efficiently to the nucleus and is targeted for degradation by the host cell proteasome machinery. We have reported that epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling negatively affects transduction by AAV2 vectors by impairing nuclear transport of the vectors. We have also observed that EGFR-PTK can phosphorylate AAV2 capsids at tyrosine residues. Tyrosine-phosphorylated AAV2 vectors enter cells efficiently but fail to transduce effectively, in part because of ubiquitination of AAV capsids followed by proteasome-mediated degradation. We reasoned that mutations of the surface-exposed tyrosine residues might allow the vectors to evade phosphorylation and subsequent ubiquitination and, thus, prevent proteasome-mediated degradation. Here, we document that site-directed mutagenesis of surface-exposed tyrosine residues leads to production of vectors that transduce HeLa cells ≈10-fold more efficiently in vitro and murine hepatocytes nearly 30-fold more efficiently in vivo at a log lower vector dose. Therapeutic levels of human Factor IX (F.IX) are also produced at an ≈10-fold reduced vector dose. The increased transduction efficiency of tyrosine-mutant vectors is due to lack of capsid ubiquitination and improved intracellular trafficking to the nucleus. These studies have led to the development of AAV vectors that are capable of high-efficiency transduction at lower doses, which has important implications in their use in human gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous mutagenesis and biophysical studies have reported the importance of some of these residues in virus assembly, production (Grieger et al., 2006; Wu et al., 2000), infectivity (Zhong et al., 2008), and pH-induced changes during trafficking (Nam et al., 2011; Salganik et al., 2012).”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Zhong et al., 2008
In the citing paper
“Therefore, mutation of surface tyrosine has been suggested, which resulted in reduced presentation of AAV capsid, decreased T-cell toxicity, and required therapeutic dose [100, 225, 229].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [229]
In the citing paper
“Since surface-exposed residues on AAV capsids can be ubiquitinated through phosphorylation, mutations of these residues (e.g. tyrosine, lysine, serine) to reduce the likelihood of ubiquitination can generate novel capsids with reduced ubiquitination, antigen presentation, and activated cellular immunity (92 -99).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [93]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648 · cited 1×
“The icosahedral two-, three- and fivefold related VP3 monomers were generated by applying icosahedral symmetry operators to a reference monomer, using the program O (46) on a Silicon graphics Octane workstation.”
MethodManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Self-citationXiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells
Muzyczka, N. (1992) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-75608-5_5 · Cited by 754 · cited 1×
“T adeno-associated virus 2 (AAV2) is a nonpathogenic human parvovirus, which has gained attention as an alternative to the more commonly used retrovirus- and adenovirusbased vectors for gene transfer and gene therapy (1, 2).”
BackgroundSelf-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“It was concluded that this CD8 T cell response to input capsid eliminated AAV2-transduced hepatocytes (43).”
BackgroundαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Cited by
Items 101–200 of 567
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
From SNPs to functional polymorphism: The insight into biotechnology applications
Liao, P.-Y., & Lee, K. H. (2010) · Biochemical Engineering Journal · doi:10.1016/j.bej.2009.12.021 · Cited by 115
van Lieshout, L. P., Domm, J. M., Rindler, T. N., Frost, K. L., Sorensen, D. L., Medina, S. J., Booth, S. A., Bridges, J. P., & Wootton, S. K. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.005 · Cited by 92
Gabriel, N., Hareendran, S., Sen, D., Gadkari, R. A., Sudha, G., Selot, R., Hussain, M., Dhaksnamoorthy, R., Samuel, R., Srinivasan, N., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.194 · Cited by 98
“More recently, site-specific mutagenesis of AAV2 capsid to generate tyrosine-mutant AAV2 vectors has demonstrated increased gene expression in vitro and in vivo (Zhong et al., 2008b; Li et al., 2010).”
BackgroundInfluentialSelf-citationAdeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 97
“Whatever the exact mechanism of endosomal escape, AAV does enter the cytoplasm where a portion of the infecting virions is subjected to phosphorylation and targeting for proteasome-mediated degradation (119, 142–144) The use of proteasomeinhibiting drugs (121, 140, 141) and surface tyrosine mutants (123, 135, 141) bot…”
BackgroundCellular transduction mechanisms of adeno-associated viral vectors
Berry, G. E., & Asokan, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.001 · Cited by 78
Evading the immune response upon in vivo gene therapy with viral vectors.
Sack, B. K., & Herzog, R. W. (2009) · PubMed · Cited by 106
Self-citationIntroducing Genes into Mammalian Cells: Viral Vectors
Sena‐Esteves, M., & Gao, G. (2020) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top095513 · Cited by 92
“This simple modification results in high-efficiency transduction by these vectors in human cells in vitro and murine hepatocytes in vivo (Zhong et al. 2008).”
BackgroundDalkara, D., Byrne, L. C., Lee, T., Hoffmann, N., Schaffer, D. V., & Flannery, J. G. (2011) · Gene Therapy · doi:10.1038/gt.2011.163 · Cited by 94
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Becker, J., Fakhiri, J., & Grimm, D. (2022) · Pathogens · doi:10.3390/pathogens11070756 · Cited by 79
“This was combined with mutations in surface-exposed tyrosine residues that have been shown previously to enhance transduction [177].”
BackgroundIshikawa, K., Fish, K. M., Tilemann, L. M., Rapti, K., Agüero, J., Santos‐Gallego, C. G., Lee, A., Karakikes, I., Xie, C., Akar, F. G., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.127 · Cited by 91
“Accordingly, attempts to produce novel vectors with clinically useful profiles were made by reengineering the capsid surface of AAV[8, 25].”
BackgroundNisanov, A. M., de Jesús, J. A. R., & Schaffer, D. V. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.056 · Cited by 89
“21 Importantly, this modification also enabled effective delivery at lower vector doses to potentially reduce immunogenicity and improve safety.”
Grimstein, C., Choi, Y., Wasserfall, C. H., Satoh, M., Atkinson, M. A., Brantly, M., Campbell‐Thompson, M., & Song, S. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-21 · Cited by 86
“Recently developed rAAV vectors including new serotypes of AAV, mutants AAV and double stranded AAV have provided more opportunities and challenges for their application [28-31].”
BackgroundQiao, C., Zhang, W., Yuan, Z., Shin, J.-H., Li, J., Jayandharan, G. R., Zhong, L., Srivastava, A., Xiao, X., & Duan, D. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.003 · Cited by 85
Self-citationSystemic gene delivery to the central nervous system using Adeno-associated virus
Bourdenx, M., Dutheil, N., Bezard, E., & Dehay, B. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00050 · Cited by 79
Guy, J. R., Qi, X., Koilkonda, R. D., Arguello, T., Chou, T.-H., Ruggeri, M., Porciatti, V., Lewin, A. S., & Hauswirth, W. W. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-3214 · Cited by 85
Advances in treatment of achondroplasia and osteoarthritis
Klag, K. A., & Horton, W. A. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv419 · Cited by 84
Liver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
“A subsequent study by the same group showed that when tyrosines at positions 444, 500, and 730 were changed to phenylalanine, a 30-fold increase in transduction was seen, in vivo [113].”
BackgroundSong, L., Kauss, M. A., Kopin, E. G., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G. R., Rivers, A. E., Aslanidi, G., Ling, C., et al. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.04.003 · Cited by 81
“Titers were determined by quantitative DNA slot blot using 32P-labeled specific DNA probes as previously described [20] or titered using a Taqman qPCR assay (21).”
InfluentialSelf-citationLi, S., Ling, C., Li, Z., Li, M., Su, Q., He, R., Tang, Q., Greiner, D. L., Shultz, L. D., Brehm, M. A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.174 · Cited by 83
Self-citationGene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
“The conversion of tyrosine residues to phenylalanine on the AAV capsid is thought to prevent ubiquitination of the virus within the host cell and subsequent degradation, thus, enhancing transduction efficiency.(33) Targeting the inner retinal layer, such as bipolar cells, has previously proven to be particularly diffi…”
Two decades of clinical gene therapy--success is finally mounting.
Herzog, R. W., Cao, O., & Srivastava, A. (2010) · PubMed · Cited by 100
Self-citationBoye, S. L., Bennett, A., Scalabrino, M. L., McCullough, K. T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., & Boye, S. E. (2016) · Journal of Virology · doi:10.1128/jvi.00200-16 · Cited by 79
Self-citationRationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS
Kanaan, N. M., Sellnow, R. C., Boye, S. L., Coberly, B., Bennett, A. D., Agbandje‐McKenna, M., Sortwell, C. E., Hauswirth, W. W., Boye, S. L., & Manfredsson, F. P. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.011 · Cited by 81
“AAV2 The packaging plasmid pACG2 for AAV2 (T2 WT) was mutated using site-directed mutagenesis to generate the capsid mutants as previously described.(6,18,21) Capsid tyrosine mutants (Table 1; Figures 2A and 2B) were generated by mutating Y444F (T2 1Y), Y444F+Y500F+ Y730F (T2 3Y), Y500F+Y730F (T2 2Y#1), Y444F+Y730F (T…”
MethodSelf-citationFull-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors
Lostal, W., Kodippili, K., Yue, Y., & Duan, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.210 · Cited by 77
“Arun Srivastava at the University of Florida) and an adenovirus helper plasmid (Stratagene, La Jolla, CA) (Zhong et al., 2008; Qiao et al., 2010; Zhang et al., 2013).”
Salganik, M., Aydemir, F., Nam, H.-J., McKENNA, R. V., Agbandje‐McKenna, M., & Muzyczka, N. (2013) · Journal of Virology · doi:10.1128/jvi.02093-13 · Cited by 80
“Srivastava and his colleagues (14) have demonstrated that mutation of Y704 and the nearby Y730 and Y700 residues to phenylalanine (Fig.”
BackgroundInfluentialSelf-citationGenetically Targeted Binary Labeling of Retinal Neurons
Zhu, Y., Xu, J., Hauswirth, W. W., & DeVries, S. H. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2960-13.2014 · Cited by 78
A simplified purification protocol for recombinant adeno-associated virus vectors
Potter, M., Lins, B., Mietzsch, M., Heilbronn, R., Van Vliet, K., Chipman, P., Agbandje-McKenna, M., Cleaver, B. D., Clément, N., Byrne, B. J., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.34 · Cited by 73
Self-citationAAV-ie-K558R mediated cochlear gene therapy and hair cell regeneration
Tao, Y., Liu, X., Liu, Y., Chu, C., Tan, F., Yu, Z., Ke, J., Li, X., Zheng, X., Zhao, X., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00938-8 · Cited by 78
Marsic, D., Govindasamy, L., Currlin, S., Markusic, D. M., Tseng, Y.-S., Herzog, R. W., Agbandje‐McKenna, M., & Zolotukhin, S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.139 · Cited by 77
Self-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
Dystrophin contains multiple independent membrane-binding domains
Zhao, J., Kodippili, K., Yue, Y., Hakim, C. H., Wasala, L. P., Pan, X., Zhang, K., Yang, N. N., Duan, D., & Lai, Y. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw210 · Cited by 79
“Y731F AAV-9 vectors were generated by transient transfection and purified through two rounds of CsCl gradient ultracentrifugation (40,41).”
MethodAdvances in AAV Vector Development for Gene Therapy in the Retina
Day, T. P., Byrne, L. C., Schaffer, D. V., & Flannery, J. G. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3209-8_86 · Cited by 78
Kay, J. D., Gouze, E., Oligino, T., Gouze, J.-N., Watson, R., Levings, P. P., Bush, M. L., Dacanay, A., Nickerson, D. M., Robbins, P. D., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1334 · Cited by 78
Hickey, D. G., Edwards, T. L., Barnard, A. R., Singh, M. S., de Silva, S. R., McClements, M. E., Flannery, J. G., Hankins, M. W., & MacLaren, R. E. (2017) · Gene Therapy · doi:10.1038/gt.2017.85 · Cited by 72
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 77
AAV Engineering for Improving Tropism to the Central Nervous System
Ghauri, M. S., & Ou, L. (2023) · Biology · doi:10.3390/biology12020186 · Cited by 73
Zhang, Y., Yue, Y., Li, L., Hakim, C. H., Zhang, K., Thomas, G. D., & Duan, D. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt224 · Cited by 71
“The Y731F tyrosine modified AAV-9 was purified and titrated according to our published protocol using a cap/rep helper plasmid generously provided by Dr Arun Srivastava (University of Florida, Gainesville, FL, USA) (38,39).”
MethodLi, M., Jayandharan, G. R., Li, B., Ling, C., Ma, W., Srivastava, A., & Li, Z. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.005 · Cited by 71
“It is interesting to note that the tyrosine-mutant efficacy data from NIH 3T3 cells are different from our previously published data with HeLa cells (Zhong et al. , 2008b), where the Y730F mutant was the most efficacious ( * 11-fold higher transduction efficiency vs. the WT vector) (Fig.”
InfluentialSelf-citationSrivastava, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.014 · Cited by 71
“Furthermore, the triple-mutant AAV2 vectors were documented to be less immunogenic since they minimize the cytotoxic T cell response by avoiding phosphorylation, ubiquitination, and proteasome-mediated degradation.(91,96,98) The NextGen AAV2 vectors have also been used in a phase I/II clinical trial and have shown cli…”
BackgroundSelf-citationLópez-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
“…ubiquitination, and proteasome-mediated degradation, improving intracellular trafficking to the nucleus and enabling a 10-fold-higher HeLa cell transduction and a 30-fold-higher mouse liver transduction [293] or higher mouse retinal cell transduction after subretinal or intravitreal delivery [294].”
BackgroundLeber's Hereditary Optic Neuropathy-Gene Therapy: From Benchtop to Bedside
Koilkonda, R. D., & Guy, J. R. (2010) · Journal of Ophthalmology · doi:10.1155/2011/179412 · Cited by 72
“Other AAVs with mutations in the capsid proteins also increase the efficiency of transgene expression [105, 106].”
BackgroundThe future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“…of the phosphorylating enzyme tyrosine kinase, or of the proteasome, enhances AAV transduction efficacy, confirming the negative effect of intracellular degradation on transduction efficacy (Zhong et al., 2008; Monahan et al., 2010; Zhang et al., 2011; Chaanine et al., 2014; Dias et al., 2019).”
BackgroundComparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8
Mietzsch, M., Barnes, C., Hull, J. A., Chipman, P. R., Xie, J., Bhattacharya, N., Sousa, D. R., McKENNA, R. V., Gao, G., & Agbandje‐McKenna, M. (2019) · Journal of Virology · doi:10.1128/jvi.01769-19 · Cited by 71
“Potential capsid engineering targets include surface-exposed tyrosine, serine, threonine, and lysine amino acids to prevent phosphorylation or ubiquitination of the capsid that leads to their degradation following cellular entry to improve gene therapy success related to transduction efficiency (68, 69).”
BackgroundSelf-citationBoye, S. L., Conlon, T. J., Erger, K. E., Ryals, R. C., Neeley, A. W., Cossette, T. L., Pang, J., Dyka, F. M., Hauswirth, W. W., & Boye, S. L. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7867 · Cited by 69
“Site-directed mutagenesis of surface-exposed tyrosine residues on the AAV2 capsid have been reported.(27) Similar methods were used to generate the AAV8(Y733F) capsid mutant described here.”
MethodKoilkonda, R., Yu, H., Talla, V., Porciatti, V., Feuer, W. J., Hauswirth, W. W., Chiodo, V., Erger, K. E., Boye, S. L., Lewin, A. S., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15388 · Cited by 65
Iida, A., Takino, N., Miyauchi, H., Shimazaki, K., & Muramatsu, S. (2013) · BioMed Research International · doi:10.1155/2013/974819 · Cited by 71
“Taken together, these results suggest that we achieved selective inhibition of AADC expression in the transduced dopaminergic cells.”
BackgroundAAV vector-mediated in vivo reprogramming into pluripotency
Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05059-x · Cited by 64
Levings, R. W., Broome, T. A., Smith, A. D., Rice, B. L., Gibbs, E. P., Myara, D. A., Hyddmark, E. V., Nasri, E., Zarezadeh, A., Levings, P. P., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.142 · Cited by 71
Öztürk, B. E., Johnson, M. E., Kleyman, M., Turunç, S., He, J., Jabalameli, S., Xi, Z., Visel, M., Dufour, V., Iwabe, S., et al. (2021) · eLife · doi:10.7554/elife.64175 · Cited by 66
Zhu, D., Brookes, D. H., Busia, A., Carneiro, A., Fannjiang, C., Popova, G., Shin, D., Donohue, K. C., Lin, L. F., Miller, Z. M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj3786 · Cited by 63
“Such mutations have also been explored previously to demonstrate enhanced transduction within various cell types ( 45 – 49 ).”
BackgroundGroße, S., Penaud‐Budloo, M., Herrmann, A.-K., Börner, K., Fakhiri, J., Laketa, V., Krämer, C., Wiedtke, E., Gunkel, M., Ménard, L., et al. (2017) · Journal of Virology · doi:10.1128/jvi.01198-17 · Cited by 70
Structure of neurotropic adeno-associated virus AAVrh.8
Halder, S., Vliet, K. V., Smith, J. K., Duong, T. T. P., McKENNA, R. V., Wilson, J. M., & Agbandje‐McKenna, M. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.08.017 · Cited by 66
“AAV2 Y704 is also part of a series of tyrosines which when mutated to phenylalanines resulted in improved intracellular trafficking to the nucleus and hence increase in transduction efficiency dependent on the cell line (Zhong et al., 2008).”
BackgroundInfluentialSelf-citationEvaluation of an optimized injection system for retinal gene therapy in human patients
Fischer, M. D., Hickey, D. G., Singh, M. S., & MacLaren, R. E. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.086 · Cited by 61
“31 Both carries important implications for the interaction between capsids and the environment.”
Fuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Applying machine learning to predict viral assembly for adeno-associated virus capsid libraries
Marques, A. D., Kummer, M., Kondratov, O., Banerjee, A., Moskalenko, O. V., & Zolotukhin, S. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.017 · Cited by 62
Self-citationCheng, B., Ling, C., Dai, Y., Lu, Y., Glushakova, L. G., Gee, S. W. Y., McGoogan, K. E., Aslanidi, G. V., Park, M., Stacpoole, P. W., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.105 · Cited by 59
Self-citationInfectious Molecular Clones of Adeno-Associated Virus Isolated Directly from Human Tissues
Schnepp, B. C., Jensen, R. L., Clark, K. R., & Johnson, P. R. (2008) · Journal of Virology · doi:10.1128/jvi.01686-08 · Cited by 60
Fakhiri, J., Schneider, M. A., Puschhof, J., Stanifer, M., Schildgen, V., Holderbach, S., Voss, Y., El Andari, J., Schildgen, O., Boulant, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.003 · Cited by 56
Site‐Specific Modification of Adeno‐Associated Viruses via a Genetically Engineered Aldehyde Tag
Liu, Y., Fang, Y. H., Zhou, Y., Zandi, E., Lee, C.-L., Joo, K., & Wang, P. (2012) · Small · doi:10.1002/smll.201201661 · Cited by 61
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
Retinal Ganglion Cell Gene Therapy and Visual System Repair
Hellström, M., & Harvey, A. R. (2011) · Current Gene Therapy · doi:10.2174/156652311794940746 · Cited by 60
Pandya, J., Ortiz, L., Ling, C., Rivers, A. E., & Aslanidi, G. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2013.74 · Cited by 55
Nuclear entry of hyperbranched polylysine nanoparticles into cochlear cells
Zhang, W., Pyykkö, I. V., Zou, J., Zhang, Y., Löbler, M., & Schmitz, K. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s16973 · Cited by 57
Adeno-Associated Virus Vector for Central Nervous System Gene Therapy
Zhu, D., Schieferecke, A. J., Lopez, P. A., & Schaffer, D. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.03.010 · Cited by 56
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
Self-citationNovel insights into gene therapy in the cornea
Mohan, R. R., Martin, L. M., & Sinha, N. R. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108361 · Cited by 56
Wang, L.-N., Wang, Y., Lu, Y., Yin, Z.-F., Zhang, Y.-H., Aslanidi, G., Srivastava, A., Ling, C., & Ling, C. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60003-0 · Cited by 54
Self-citationSong, L., Li, X., Jayandharan, G. R., Wang, Y., Aslanidi, G. V., Ling, C., Zhong, L., Gao, G., Yoder, M. C., Ling, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058757 · Cited by 54
“Based on our recent studies with tyrosine-mutant AAV2 and AAV3 serotype vectors [15,17], we favor the hypothesis that improved intracel-”
MethodSelf-citationGene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients
Colella, P., & Auricchio, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.123 · Cited by 59
“…et al., 2001; Lotery et al., 2003; Allocca et al., 2007; Mussolino et al., 2011a); and (iii) the generation of tyrosine-mutated AAV capsids (Zhong et al., 2008b) that avoid targeting of AAVs to the proteasome, thus increasing the vector load that reaches the nucleus, resulting in increased…”
BackgroundBoisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Enoki, R., Oda, Y., Mieda, M., Ono, D., Honma, S., & Honma, K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616815114 · Cited by 54
“Srivastava, University of Florida, Gainesville, FL) (48) was produced using a triple-transfection, helper-free method and was purified as described previously (49).”
Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa
Mowat, F. M., Occelli, L. M., Bartoe, J. T., Gervais, K. J., Bruewer, A. R., Querubin, J. R., Dinculescu, A., Boye, S. L., Hauswirth, W. W., & Petersen‐Jones, S. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00342 · Cited by 56
“AAV Constructs Recombinant AAV vectors were manufactured and purified by previously described methods, (Hauswirth et al., 2000; Zolotukhin et al., 2002; Zhong et al., 2008; Pang et al., 2011; Petrs-Silva et al., 2011) including purification and concentration by column chromatography.”
MethodCharbel Issa, P., De Silva, S. R., Lipinski, D. M., Singh, M. S., Mouravlev, A., You, Q., Barnard, A. R., Hankins, M. W., During, M. J., & MacLaren, R. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060361 · Cited by 53
“Hence, it is unlikely that the reduced transduction is due to increased ubiquitin-tagged proteasome-mediated degradation [20], as one might observe if greater numbers of tyrosine residues were present on the hybrid”
Rational engineering of a functional CpG-free ITR for AAV gene therapy
Pan, X., Yue, Y., Boftsi, M., Wasala, L. P., Tran, N. T., Zhang, K., Pintel, D. J., Tai, P. W. L., & Duan, D. (2022) · Gene Therapy · doi:10.1038/s41434-021-00296-0 · Cited by 53
Parvoviruses: Structure and Infection
Halder, S., Ng, R., & Agbandje‐McKenna, M. (2012) · Future Virology · doi:10.2217/fvl.12.12 · Cited by 57
Self-citationCalpain-mediated cleavage of collapsin response mediator protein-2 drives acute axonal degeneration
Zhang, J.-N., Michel, U., Lenz, C., Friedel, C. C., Köster, S., d’Hedouville, Z., Tönges, L., Urlaub, H., Bähr, M., Lingor, P., et al. (2016) · Scientific Reports · doi:10.1038/srep37050 · Cited by 54
Structural Insights into Human Bocaparvoviruses
Mietzsch, M., Kailasan, S., Garrison, J., Ilyas, M., Chipman, P. R., Kantola, K., Janssen, M. E. W., Spear, J. M., Sousa, D. R., McKENNA, R. V., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00261-17 · Cited by 53
Self-citationAdipose Tissue: An Emerging Target for Adeno-associated Viral Vectors
Bates, R., Huang, W., & Cao, L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.009 · Cited by 54
“One approach to targeting tissues more efficiently is to make particular point mutations on the viral capsid to avoid proteasome-mediated destruction through ubiquitination.(96) Mutating tyrosine to phenylalanine on the AAV2 capsid has been shown to increase transduction in hepatocytes and other tissues.”
BackgroundGene therapy in animal models of autosomal dominant retinitis pigmentosa.
Rossmiller, B. P., Mao, H., & Lewin, A. S. (2012) · PubMed Central · Cited by 70
Nance, M. E., & Duan, D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.107 · Cited by 57
“115 Martino and colleagues evaluated immunological benefits of tyrosine mutated AAV-2.”
Wang, M., Sun, J., Crosby, A. J., Woodard, K., Hirsch, M. L., Samulski, R. J., & Li, C. (2016) · Gene Therapy · doi:10.1038/gt.2016.75 · Cited by 53
Wagner, H. J., Weber, W., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202004018 · Cited by 54
Molday, L. L., Djajadi, H. R., Yan, P., Szczygiel, L., Boye, S. L., Chiodo, V. A., Gregory-Evans, K., Šarunic, M. V., Hauswirth, W. W., & Molday, R. S. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt244 · Cited by 52
Mukherjee, S., Kuroiwa, M., Oakden, W., Paul, B. T., Noman, A., Chen, J., Lin, V., Dimitrijevic, A., Stanisz, G. J., & Le, T. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.07.013 · Cited by 53
Aslanidi, G., Rivers, A. E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G. R., Zolotukhin, S., Agbandje‐McKenna, M., & Srivastava, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.03.079 · Cited by 52
“Our recent data with AAV2 serotype vectors indicate that a single substitution of tyrosine to phenylalanine (Y→F) dramatically improves viral trafficking from endosome to the nucleolus by preventing capsid phosphorylation, subsequent ubiquitination and degradation via proteasome [17].”
BackgroundMethodSelf-citationSite-Specific N-Glycosylation on the AAV8 Capsid Protein
Aloor, A., Zhang, J., Gashash, E. A., Parameswaran, A., Chrzanowski, M., Ma, C., Diao, Y., Wang, P. G., & Xiao, W. (2018) · Viruses · doi:10.3390/v10110644 · Cited by 51
“Site specific modifications of capsid proteins like tyrosine phosphorylation is reported to promote ubiquitination and degradation of AAV2 capsid protein leading to decreased tropism [30].”
BackgroundWang, H., Murphy, R., Taaffe, D., Yin, S., Xia, L., Hauswirth, W. W., Bance, M., Robertson, G. S., & Wang, J. (2011) · Gene Therapy · doi:10.1038/gt.2011.91 · Cited by 53
“This mutation was designed to reduced degradation of the virus in the cytoplasm so that more vector reaches the nucleus”
BackgroundOptimization of AAV vectors to target persistent viral reservoirs
Colón-Thillet, R., Jerome, K. R., & Stone, D. (2021) · Virology Journal · doi:10.1186/s12985-021-01555-7 · Cited by 50
“Examples of this approach include direct modification of single surface-exposed tyrosine residues to phenylalanine, preventing tyrosine-mediated ubiquitination and degradation of capsids after internalization [82]; substitution of variable loop domain residues to create a capsid with reduced immunogenicity [83]; or th…”
BackgroundThe curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Tropism-modified AAV Vectors Overcome Barriers to Successful Cutaneous Therapy
Sallach, J., Pasquale, G. D., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S. A., Ulus, H., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.14 · Cited by 54
Chuah, M., Evens, H., & VandenDriessche, T. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12215 · Cited by 58
Nicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48
“For example, the elimination of certain tyrosines on the capsids of AAV2 and AAV6 has allowed for enhanced transduction efficiency and lower rates of proteasomal degradation (29, 30, 73); however, it has been shown that this strategy cannot be applied to rAAV9 and attempts with rAAV8 have produced mixed results (74, 7…”
BackgroundResultKoilkonda, R. D. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.135 · Cited by 48
Shin, J.-H., Yue, Y., Srivastava, A., Smith, B., Lai, Y., & Duan, D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.147 · Cited by 47
“The Y445F tyrosine modified AAV-6 was purified through three rounds of cesium chloride isopycnic ultracentrifugation using our published protocol (Zhong et al., 2008; Qiao et al., 2010).”
MethodInfluentialSelf-citationvan Lieshout, L. P., Soule, G., Sorensen, D., Frost, K. L., He, S., Tierney, K. J., Safronetz, D., Booth, S. A., Kobinger, G., Qiu, X., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix644 · Cited by 49
Structural and cellular biology of adeno-associated virus attachment and entry
Zengel, J. R., & Carette, J. E. (2020) · Advances in virus research · doi:10.1016/bs.aivir.2020.01.002 · Cited by 54
Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes
Hui, D. J., Basner-Tschakarjan, E., Chen, Y., Davidson, R. J., Buchlis, G., Yazicioglu, M., Pien, G. C., Finn, J. D., Haurigot, V., Tai, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.166 · Cited by 47
Ku, C. A., Chiodo, V. A., Boye, S. L., Goldberg, A. F. X., Li, T., Hauswirth, W. W., & Ramamurthy, V. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr391 · Cited by 49
Metadata
- Authors
- Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., Muzyczka, N., & Srivastava, A.
- Affiliations
- *Division of Cellular and Molecular Therapy, Department of Pediatrics,
- Powell Gene Therapy Center and Genetics Institute,
- University of Florida Health (US)
- UF Health Cancer Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-06-03
- Volume
- 105
- Issue
- 22
- Pages
- 7827-7832
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2402387
- OpenAlex
- W2122236774
- Cited by
- 558
- References
- 53
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 30 · 2023: 31 · 2022: 29 · 2021: 43 · 2020: 38 · 2019: 31 · 2018: 27 · 2017: 34 · 2016: 29 · 2015: 38 · 2014: 34 · 2013: 44 · 2012: 24
- FWCI
- 18.28
- Type
- journal article
- Language
- en
- Update notices
- correction (2008-08-05)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- National Institutes of Health (Project 3)
- National Heart, Lung, and Blood Institute (P01-HL51811, P01HL059412, P01HL051811, R01 HL-07691, R01HL065570, R01HL-65570, P01HL078810)
- National Institute of General Medical Sciences (R01GM082946)
- National Institute of Allergy and Infectious Diseases (R01AI051390)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, R01DK062302)
- National Institute of Biomedical Imaging and Bioengineering (R01EB002073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- tyrosine mutations, proteasomal degradation, nuclear transport, transduction efficiency, factor IX, gene therapy vectors, hepatocytes
- MeSH terms
- Dependovirus, Animals, Capsid, Cell Nucleus, Genetic Vectors, HeLa Cells, Humans, Mice, Inbred C57BL, Phosphorylation, Transduction, Genetic, Tyrosine, Genetic Therapy, Point Mutation, Hepatocytes, Mice, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.